Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 355

1.

PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis.

Squizzato A, Suter MB, Nerone M, Giugliano RP, Dentali F, Maresca AM, Campiotti L, Grandi AM, Guasti L.

Intern Emerg Med. 2017 Jul 10. doi: 10.1007/s11739-017-1708-7. [Epub ahead of print]

PMID:
28695455
2.

Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial.

Eisen A, Ruff CT, Braunwald E, Hamershock RA, Lewis BS, Hassager C, Chao TF, Le Heuzey JY, Mercuri M, Rutman H, Antman EM, Giugliano RP.

J Am Heart Assoc. 2017 Jun 30;6(7). pii: e006035. doi: 10.1161/JAHA.117.006035.

3.

Major Bleeding in Patients With Diabetes and Atrial Fibrillation Treated With New Oral Anticoagulants-Reply.

Plitt A, McGuire DK, Giugliano RP.

JAMA Cardiol. 2017 Jun 28. doi: 10.1001/jamacardio.2017.2034. [Epub ahead of print] No abstract available.

PMID:
28658488
4.

Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective.

Vilain KA, Yang MC, Hui Tan EC, Wang K, Li H, Hsu WH, Giugliano RP, Cohen DJ, Magnuson EA; ENGAGE AF – TIMI 48 Investigators.

Value Health Reg Issues. 2017 May;12:74-83. doi: 10.1016/j.vhri.2017.03.011. Epub 2017 May 17.

PMID:
28648320
5.

Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of randomized controlled trials.

Wang KL, Chiu CC, Su-Yin Tan D, Lin CY, Lai EY, Goto S, Giugliano RP, Chiang CE.

J Formos Med Assoc. 2017 Jun 20. pii: S0929-6646(17)30146-8. doi: 10.1016/j.jfma.2017.05.015. [Epub ahead of print]

6.

First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial.

Steffel J, Ruff CT, Hamershock RA, Murphy SA, Senior R, Roy D, Lanz HJ, Mercuri MF, Antman EM, Giugliano RP.

Int J Cardiol. 2017 Jun 2. pii: S0167-5273(17)32088-0. doi: 10.1016/j.ijcard.2017.05.098. [Epub ahead of print]

PMID:
28625512
7.

Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).

Pokharel Y, Chinnakondepalli K, Vilain K, Wang K, Mark DB, Davies G, Blazing MA, Giugliano RP, Braunwald E, Cannon CP, Cohen DJ, Magnuson EA.

Circ Cardiovasc Qual Outcomes. 2017 May;10(5). pii: e003201. doi: 10.1161/CIRCOUTCOMES.116.003201.

PMID:
28506979
8.

Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review.

Abell JE, Laing SM, Barker TC, Norry EC, Starzyk K, Goodman SG, Dellborg M, Steg PG, Giugliano RP.

Eur Heart J Cardiovasc Pharmacother. 2017 Apr 18. doi: 10.1093/ehjcvp/pvx007. [Epub ahead of print]

PMID:
28430984
9.

Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites.

Koshizaka M, Lopes RD, Newby LK, Clare RM, Schulte PJ, Tricoci P, Mahaffey KW, Ogawa H, Moliterno DJ, Giugliano RP, Huber K, James S, Harrington RA, Alexander JH.

Am J Med. 2017 Apr 8. pii: S0002-9343(17)30357-1. doi: 10.1016/j.amjmed.2017.03.030. [Epub ahead of print]

PMID:
28396226
10.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators.

N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.

PMID:
28304224
11.

Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.

De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, Ruff CT, Antman EM, Braunwald E, Giugliano RP.

J Am Coll Cardiol. 2017 Mar 21;69(11):1372-1382. doi: 10.1016/j.jacc.2016.12.031.

12.

Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease.

Renda G, Ricci F, Giugliano RP, De Caterina R.

J Am Coll Cardiol. 2017 Mar 21;69(11):1363-1371. doi: 10.1016/j.jacc.2016.12.038.

13.

Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.

Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal FJ.

JAMA Cardiol. 2017 Jun 1;2(6):598-607. doi: 10.1001/jamacardio.2017.0747.

PMID:
28291870
14.

Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial.

Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, White JA, Tershakovec AM, Cannon CP, Braunwald E.

JAMA Cardiol. 2017 May 1;2(5):547-555. doi: 10.1001/jamacardio.2017.0083.

PMID:
28291866
15.

Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.

Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park JG, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon CP, Braunwald E.

J Am Coll Cardiol. 2017 Feb 28;69(8):911-921. doi: 10.1016/j.jacc.2016.11.070.

PMID:
28231942
16.

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.

Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M, Nordio F, Mercuri MF, Antman E, Giugliano RP; ENGAGE AF-TIMI 48 Investigators.

Circulation. 2017 Mar 28;135(13):1273-1275. doi: 10.1161/CIRCULATIONAHA.116.026714. Epub 2017 Feb 16. No abstract available.

PMID:
28209729
17.

Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial.

Giugliano RP, Mach F, Zavitz K, Kurtz C, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Honarpour N, Wasserman SM, Ott BR; EBBINGHAUS Investigators.

Clin Cardiol. 2017 Feb;40(2):59-65. doi: 10.1002/clc.22678. Epub 2017 Feb 16.

18.

Atrial Fibrillation, Type 2 Diabetes, and Non-Vitamin K Antagonist Oral Anticoagulants: A Review.

Plitt A, McGuire DK, Giugliano RP.

JAMA Cardiol. 2017 Apr 1;2(4):442-448. doi: 10.1001/jamacardio.2016.5224.

PMID:
28122078
19.

Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.

Desai NR, Giugliano RP, Wasserman SM, Gibbs JP, Liu T, Scott R, Sabatine MS.

JAMA Cardiol. 2017 May 1;2(5):556-560. doi: 10.1001/jamacardio.2016.5395.

PMID:
28122070
20.

Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS.

Farhan S, Clare RM, Jarai R, Giugliano RP, Lokhnygina Y, Harrington RA, Kristin Newby L, Huber K.

Int J Cardiol. 2017 Apr 1;232:264-270. doi: 10.1016/j.ijcard.2017.01.007. Epub 2017 Jan 4.

PMID:
28089149

Supplemental Content

Loading ...
Support Center